ME vs. FHTX, VERU, CDT, ACIU, ALDX, HOWL, EBS, QURE, PBYI, and TSVT
Should you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include Foghorn Therapeutics (FHTX), Veru (VERU), Conduit Pharmaceuticals (CDT), AC Immune (ACIU), Aldeyra Therapeutics (ALDX), Werewolf Therapeutics (HOWL), Emergent BioSolutions (EBS), uniQure (QURE), Puma Biotechnology (PBYI), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
23andMe (NASDAQ:ME) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Foghorn Therapeutics received 20 more outperform votes than 23andMe when rated by MarketBeat users. However, 63.16% of users gave 23andMe an outperform vote while only 59.26% of users gave Foghorn Therapeutics an outperform vote.
23andMe has a net margin of -210.48% compared to Foghorn Therapeutics' net margin of -274.23%. Foghorn Therapeutics' return on equity of 0.00% beat 23andMe's return on equity.
23andMe currently has a consensus target price of $0.47, suggesting a potential downside of 19.90%. Foghorn Therapeutics has a consensus target price of $14.50, suggesting a potential upside of 163.16%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Foghorn Therapeutics is more favorable than 23andMe.
36.1% of 23andMe shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 27.6% of 23andMe shares are owned by company insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, 23andMe had 4 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 5 mentions for 23andMe and 1 mentions for Foghorn Therapeutics. 23andMe's average media sentiment score of 0.08 beat Foghorn Therapeutics' score of 0.00 indicating that 23andMe is being referred to more favorably in the media.
Foghorn Therapeutics has lower revenue, but higher earnings than 23andMe. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than 23andMe, indicating that it is currently the more affordable of the two stocks.
23andMe has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.15, indicating that its stock price is 215% more volatile than the S&P 500.
Summary
Foghorn Therapeutics beats 23andMe on 10 of the 18 factors compared between the two stocks.
Get 23andMe News Delivered to You Automatically
Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
